Recent Company News

• 04:50 AM ET Aug 11, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:32 PM ET Aug 10, 2026
  

  Lakefront Biotherapeutics reports H1 EPS €0.25 vs year-ago (€3.93) (€23.44, 0.00)

• 10:02 AM ET Aug 06, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (158 total)

• 10:05 AM ET Aug 03, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (162 total)

• 08:41 AM ET Jul 10, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:13 AM ET Jul 10, 2026
  

  Lakefront Biotherapeutics resumed equal-weight at Morgan Stanley ($30.59, 0.00)

• 07:55 AM ET Jun 16, 2026
  

  FDA grants orphan drug designation to GLPG3667 for dermatomyositis (€24.56, -0.52)

• 04:02 PM ET Jun 09, 2026
  

  Lakefront Biotherapeutics announces initiation of €50M stock repurchase program (€24.24, 0.00)

• 04:02 PM ET Jun 08, 2026
  

  Lakefront Biotherapeutics appoints Eric Hedrick as Chief Medical Officer (€24.36, 0.00)

• 04:20 PM ET Jun 04, 2026
  

  Gilead Sciences, Lakefront complete acquisition of Ouro Medicines ($129.18, 0.00)